Sartorius Stedim Biotech SA (SDMHF)
247.25
0.00 (0.00%)
USD |
OTCM |
Dec 05, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 40.92% |
| Valuation | |
| PE Ratio | 82.54 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.391 |
| Price to Book Value | 5.072 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.7448 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.635 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 75.34% |
Profile
| Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The firm offers a broad portfolio of products that focuses on all steps in the manufacture of a biopharmaceutical, as well as in process development as prerequisite procedures. Its technologies cover inter alia, cell line technologies, cell culture media, bioreactors, and a wide range of products for separation, purification, and concentration of biological intermediates and finished products, as well as solutions for storage and transportation. It also offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. The company was founded on September 28, 1978 and is headquartered in Aubagne, France. |
| URL | http://www.sartorius.com |
| Investor Relations URL | https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations |
| HQ State/Province | Provence-Alpes-Cote-dAzur |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 16, 2026 (est.) |
| Last Earnings Release | Oct. 16, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 03, 2025 |
Ratings
Profile
| Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The firm offers a broad portfolio of products that focuses on all steps in the manufacture of a biopharmaceutical, as well as in process development as prerequisite procedures. Its technologies cover inter alia, cell line technologies, cell culture media, bioreactors, and a wide range of products for separation, purification, and concentration of biological intermediates and finished products, as well as solutions for storage and transportation. It also offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. The company was founded on September 28, 1978 and is headquartered in Aubagne, France. |
| URL | http://www.sartorius.com |
| Investor Relations URL | https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations |
| HQ State/Province | Provence-Alpes-Cote-dAzur |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 16, 2026 (est.) |
| Last Earnings Release | Oct. 16, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 03, 2025 |